AngioDynamics (ANGO) Downgraded to “Hold” at ValuEngine

ValuEngine lowered shares of AngioDynamics (NASDAQ:ANGO) from a buy rating to a hold rating in a report issued on Friday morning, ValuEngine reports.

A number of other brokerages have also commented on ANGO. BidaskClub raised shares of AngioDynamics from a buy rating to a strong-buy rating in a report on Monday, April 1st. Zacks Investment Research lowered shares of AngioDynamics from a buy rating to a hold rating in a report on Wednesday, March 13th. Finally, Canaccord Genuity increased their price target on shares of AngioDynamics from $20.00 to $23.00 and gave the stock a hold rating in a report on Monday, January 7th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $23.50.

Shares of NASDAQ:ANGO opened at $20.06 on Friday. The firm has a market capitalization of $752.88 million, a PE ratio of 27.11 and a beta of 0.75. AngioDynamics has a one year low of $18.11 and a one year high of $25.48. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.70 and a current ratio of 2.68.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Tuesday, April 2nd. The medical instruments supplier reported $0.19 EPS for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.03). The company had revenue of $86.34 million during the quarter, compared to the consensus estimate of $88.30 million. AngioDynamics had a return on equity of 5.41% and a net margin of 1.30%. AngioDynamics’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.23 EPS. Research analysts expect that AngioDynamics will post 0.83 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. Thrivent Financial for Lutherans boosted its stake in shares of AngioDynamics by 2.2% in the 4th quarter. Thrivent Financial for Lutherans now owns 26,360 shares of the medical instruments supplier’s stock valued at $531,000 after purchasing an additional 579 shares in the last quarter. Advisor Group Inc. boosted its stake in shares of AngioDynamics by 21.4% in the 4th quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 601 shares in the last quarter. Texas Permanent School Fund boosted its stake in shares of AngioDynamics by 4.1% in the 4th quarter. Texas Permanent School Fund now owns 24,292 shares of the medical instruments supplier’s stock valued at $489,000 after purchasing an additional 964 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of AngioDynamics by 28.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 1,181 shares in the last quarter. Finally, United Services Automobile Association boosted its stake in shares of AngioDynamics by 9.8% in the 4th quarter. United Services Automobile Association now owns 17,816 shares of the medical instruments supplier’s stock valued at $359,000 after purchasing an additional 1,595 shares in the last quarter. 99.71% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Further Reading: What is a Lock-Up Period?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit